These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32173467)

  • 1. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells.
    Zhao K; Lu Y; Chen Y; Cheng J; Zhang W
    Exp Cell Res; 2020 May; 390(2):111942. PubMed ID: 32173467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
    Spender LC; Ferguson GJ; Liu S; Cui C; Girotti MR; Sibbet G; Higgs EB; Shuttleworth MK; Hamilton T; Lorigan P; Weller M; Vincent DF; Sansom OJ; Frame M; Dijke PT; Marais R; Inman GJ
    Oncotarget; 2016 Dec; 7(50):81995-82012. PubMed ID: 27835901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
    Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
    Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

  • 5. Signal transducer and activator of transcription 3 inhibition enhances vemurafenib sensitivity in colon cancers harboring the BRAF
    Wang K; Li Y; Song N; Che X; Hou K; Xu L; Bai M; Wang Q; Wang Y; Zhou Y; Cao M; Liu Y; Zhang J
    J Cell Biochem; 2019 Apr; 120(4):5315-5325. PubMed ID: 30320916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting mitochondria in melanoma: Interplay between MAPK signaling pathway and mitochondrial dynamics.
    Ferraz LS; Costa RTD; Costa CAD; Ribeiro CAJ; Arruda DC; Maria-Engler SS; Rodrigues T
    Biochem Pharmacol; 2020 Aug; 178():114104. PubMed ID: 32562785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells.
    Notarangelo T; Sisinni L; Trino S; Calice G; Simeon V; Landriscina M
    Cancer Lett; 2018 Oct; 433():147-155. PubMed ID: 29969659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
    Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
    J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
    Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
    Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
    Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
    Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
    Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CDC7 sensitizes resistance melanoma cells to BRAF
    Gad SA; Ali HEA; Gaballa R; Abdelsalam RM; Zerfaoui M; Ali HI; Salama SH; Kenawy SA; Kandil E; Abd Elmageed ZY
    Sci Rep; 2019 Oct; 9(1):14197. PubMed ID: 31578454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.
    Mologni L; Costanza M; Sharma GG; Viltadi M; Massimino L; Citterio S; Purgante S; Raman H; Pirola A; Zucchetti M; Piazza R; Gambacorti-Passerini C
    Neoplasia; 2018 May; 20(5):467-477. PubMed ID: 29605720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HI-511 overcomes melanoma drug resistance
    Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
    Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
    [No Abstract]   [Full Text] [Related]  

  • 18. Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma.
    Park BS; Jeon H; Kim Y; Kwon H; Choi GE; Chi SG; Park HM; Lee H; Kim T
    Mol Cancer; 2024 Jul; 23(1):136. PubMed ID: 38965534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
    Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L
    Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
    Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
    Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.